TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3901535

Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0 to 120 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Secretin and CCK (1 IU/kg/h, 60 to 120 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Secretin and CCK
Number of subjects: 15
Study: 31615181

Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao Powder (JWXYP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 28825508

Group type: EXPERIMENTAL
Intervention: Memory specificity training (MEST)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Life review
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 26066525

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (70 mg for 16 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25274892

Group type: EXPERIMENTAL
Intervention: Combination of 3 synthetic disease-modifying antirheumatic drugs (sDMARD) and prednisolone (PRD), with infliximab or placebo infusions during the first 6 months
Number of subjects: 99
Study: 23239968

Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 7.5 µg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 15 µg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 45 µg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 90 µg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 19882529

Group type: EXPERIMENTAL
Intervention: Oral magnesium therapy (300 mg magnesium citrate for 1 month)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study: 17845256

Group type: EXPERIMENTAL
Intervention: Non-WBC-reduced ABT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RBCs or whole blood filtered after storage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prestorage-filtered RBCs
Number of subjects: 12
Study: 14705233

Group type: EXPERIMENTAL
Intervention: N of 1 trials with diclofenac 50 mg and misoprostol 200 microg twice a day for 2 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional treatment (stopping NSAID and waiting)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: N of 1 trials with diclofenac
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 51
Study: 12085291

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for plantar fasciitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for lateral elbow epicondylitis (tennis elbow)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for calcifying tendinitis of the rotator cuff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled trials of ESWT
Number of subjects: 0
Study: 9840847

Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine/Sufentanil/Clonidine (BESC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine/Clonidine (BEC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine/Sufentanil (BES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine/Epinephrine (BE)
Number of subjects: 100
Study: 8134190

Group type: EXPERIMENTAL
Intervention: Supplementation with calcium and phosphorus (enterally and/or parenterally)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 74
Study: 2510258

Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 12
Study: 29447737

Group type: EXPERIMENTAL
Intervention: Morbidity events before month 3 in SERAPHIN study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morbidity events before month 3 in GRIPHON study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morbidity events at 6-month and 12-month landmarks
Number of subjects: 0
Study: 28668412

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC) in 1, 2, and 3 vessels
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Extensive calcification (CACSIS>5)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Major non-coronary atherosclerosis cardiovascular findings (NCACVF)
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: None or minimal NCACVF
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Age as a predictor of death
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: History of malignancy as a predictor of death
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: NCACVF class as a predictor of death
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: CACSIS as a predictor of death among patients without malignancy
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 1901
Study: 26248171

Group type: EXPERIMENTAL
Intervention: 8-session sexual risk reduction intervention
Number of subjects: 763

Group type: COMPARATOR
Intervention: 8-session general health intervention (control)
Number of subjects: 763
Study: 23997361

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy (Thornton Adjustable Positioner type‐1, Airway Management, Inc., Dallas, TX, USA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 103
Study: 21050560

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Band ligation
Number of subjects: 42
Study: 18755566

Group type: EXPERIMENTAL
Intervention: Pictograph
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 2412

Group type: COMPARATOR
Intervention: All formats
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Verbatim and gist knowledge
Number of subjects: 2412
Study: 15973829

Group type: EXPERIMENTAL
Intervention: 600‐grit ground plus silanation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: air‐particle abrasion plus silanation
Number of subjects: 24

Group type: COMPARATOR
Intervention: 600‐grit ground only
Number of subjects: 24

Group type: COMPARATOR
Intervention: 600‐grit ground plus air‐particle abrasion
Number of subjects: 24
Study: 12935441

Group type: EXPERIMENTAL
Intervention: Intravenous liposomal all-trans-retinoic acid (L-ATRA) 90 mg/m² every other day for 15 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oral ATRA (Vesanoid) 45 mg/m² daily for 15 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous liposomal all-trans-retinoic acid (L-ATRA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous liposomal all-trans-retinoic acid (L-ATRA) and Oral ATRA
Number of subjects: 29
Study: 10827385

Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole
Number of subjects: 491

Group type: COMPARATOR
Intervention: Conventional pretreatment (heparin and aspirin)
Number of subjects: 491
Study: 8702050

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 62
Study: 1712433

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 19
Study: 6851813

Group type: EXPERIMENTAL
Intervention: Angiografin mixed with lidocaine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Hexabrix
Number of subjects: 92
Study: 31958293

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amoxicillin-metronidazole
Number of subjects: 42
Study: 31026384

Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Number of subjects: 49
Study: 29465097

Group type: EXPERIMENTAL
Intervention: Motivators to physical activity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Barriers to physical activity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intention to increase walking
Number of subjects: 50
Study: 27057878

Group type: EXPERIMENTAL
Intervention: Chest compressions with PPE
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chest compressions without PPE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Physiological parameters with PPE
Number of subjects: 40
Study: 25439136

Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 I.U.) plus zinc sulfate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vitamin A (200,000 I.U.) plus placebo
Number of subjects: 24
Study: 22739142

Group type: EXPERIMENTAL
Intervention: LX4211 150 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LX4211 300 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LX4211 300 mg (follow-up single-dose study)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19664264

Group type: EXPERIMENTAL
Intervention: High intensity shoulder elevation
Number of subjects: 18
Study: 16909876

Group type: EXPERIMENTAL
Intervention: Spatial cuing (automated aid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text cuing (automated aid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No assistance (Control group)
Number of subjects: 0
Study: 12781596

Group type: EXPERIMENTAL
Intervention: tolcapone (two doses)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PIMS scores
Number of subjects: 116
Study: 11187914

Group type: EXPERIMENTAL
Intervention: Induction treatment without asparaginase (ASP)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: CNS control without cranial irradiation
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: 24-hour daunorubicin (DNR) infusion
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: DNR response
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Rapid rotation regimen
Number of subjects: 1191

Group type: COMPARATOR
Intervention: 6-thioguanine (6-TG) in maintenance treatment
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Intensification of systemic treatment
Number of subjects: 1191
Study: 8838763

Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA; 11 weeks to 12 weeks and 6 days)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (MA; 15 weeks to 16 weeks and 6 days)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (MA)
Number of subjects: 683
Study: 1283570

Group type: EXPERIMENTAL
Intervention: Verapamil SR 480 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil IR (80 or 160 mg 3 times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil SR and IR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil IR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil SR
Number of subjects: 0
Study: 6431471

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing arousal during material presentation
Number of subjects: 0
Study: 31004517

Group type: EXPERIMENTAL
Intervention: Standard tablet (ST‐OS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Suspension in solid lipid nanoparticles (SLN-OS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal jellified melatonin microemulsion (μE-TD)
Number of subjects: 21
Study: 28623849

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) free base
Number of subjects: 49
Study: 27048477

Group type: EXPERIMENTAL
Intervention: Technology-assisted Cascade Training and Supervision (TACTS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Specialist-delivered training
Number of subjects: 80
Study: 25112783

Group type: EXPERIMENTAL
Intervention: Plantago ovata husk
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Initial situation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fiber treatment (Plantago ovata husk)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 22575433

Group type: EXPERIMENTAL
Intervention: Pictorial images and electronic drug monitoring (EDM) review used in counseling
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Counseling tools (pictorial images and EDM)
Number of subjects: 204
Study: 19602273

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (24 weeks)
Number of subjects: 414
Study: 17470863

Group type: EXPERIMENTAL
Intervention: Aerobic exercise therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Exercise-placebo (body conditioning)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 16921051

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD) for 7 months followed by continuous AD
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD) for 7 months followed by intermittent AD
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Androgen deprivation (AD) for 7 months
Number of subjects: 1345
Study: 12972790

Group type: EXPERIMENTAL
Intervention: Telephone reminder/recall
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 1203
Study: 11059179

Group type: EXPERIMENTAL
Intervention: Healthy elderly subjects (above the age of 60 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Young volunteers
Number of subjects: 60
Study: 8849215

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Penicillin V (50,000 U/kg/day in two divided doses for 10 days)
Number of subjects: 154
Study: 1627425

Group type: EXPERIMENTAL
Intervention: Neural-network-based artificial intelligence for treatment decision-making
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Neural-network technique
Number of subjects: 9000
Study: 6744791

Group type: EXPERIMENTAL
Intervention: Endurance training for 36 weeks
Number of subjects: 6
Study: 29903720

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 73
Study: 29317418

Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 55
Study: 27748575

Group type: EXPERIMENTAL
Intervention: Routine oral care with tongue cleaning (intervention group; n = 58)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine oral care alone (control group; n = 56)
Number of subjects: 114
Study: 24708472

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived MSCs (1 × 10^6 cells/kg of body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 22048283

Group type: EXPERIMENTAL
Intervention: Oral Passiflora incarnata Linneaus extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20084463

Group type: EXPERIMENTAL
Intervention: Physical activity at an intensity >3 METs
Number of subjects: 183
Study: 18096343

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (20mg, 2ml, Hyalgan)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sodium chloride (control group)
Number of subjects: 56
Study: 16003527

Group type: EXPERIMENTAL
Intervention: Ropinirole alone or in combination with L-dopa
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 453
Study: 11826422

Group type: EXPERIMENTAL
Intervention: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo with interferon alfa-2a
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Amantadine therapy
Number of subjects: 246

Group type: COMPARATOR
Intervention: Amantadine and placebo
Number of subjects: 246
Study: 10397536

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (20 mg pentavalent antimony per kg per day for 28 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Amphotericin B (0.7 mg/kg per day for 28 days)
Number of subjects: 89
Study: 7740021

Group type: EXPERIMENTAL
Intervention: fitness
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: fitness + school nutrition
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: school-based nutrition
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: school + home nutrition
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: home-based nutrition
Number of subjects: 1147

Group type: COMPARATOR
Intervention: control group
Number of subjects: 1147
Study: 2202954

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 300
Study: 6993035

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy with levamisole (2.5 mg/kg orally for 2 consecutive days each week while off chemotherapy)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Chemotherapy alone (standard regimen of cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy with levamisole
Number of subjects: 77

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 77
Study: 31430414

Group type: EXPERIMENTAL
Intervention: LINK (buprenorphine induction, in-patient dose stabilization and post-discharge transition to maintenance buprenorphine)
Number of subjects: 115

Group type: COMPARATOR
Intervention: WM (5-day buprenorphine managed withdrawal protocol)
Number of subjects: 115
Study: 29458934

Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with lavender oil for 5 sessions over 3 cycles
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 77
Study: 28322468

Group type: EXPERIMENTAL
Intervention: Dedicated dietitian (DD)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Trained hospital dietitian (THD)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Existing practice (EP)
Number of subjects: 178
Study: 26261640

Group type: EXPERIMENTAL
Intervention: Ginsenosides (GS) + Ulinastatin (UTI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ulinastatin (UTI)
Number of subjects: 80
Study: 24061340

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 272
Study: 21436337

Group type: EXPERIMENTAL
Intervention: Magnetization Transfer Imaging (MTI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 18251615

Group type: EXPERIMENTAL
Intervention: Group B (American Orthodontics, AISI 316L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group C (Dentaurum, AISI 316L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group A (3M/Unitek, AISI 303)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30
Study: 16646673

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) plus G-CSF
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) plus GM-CSF
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) plus GM-CSF followed by G-CSF
Number of subjects: 29

Group type: COMPARATOR
Intervention: GM-CSF-containing regimen
Number of subjects: 29
Study: 12692927

Group type: EXPERIMENTAL
Intervention: Public health nursing visit awareness
Number of subjects: 10749

Group type: EXPERIMENTAL
Intervention: Visiting nursing agencies' service awareness
Number of subjects: 10749

Group type: EXPERIMENTAL
Intervention: Desire to use public health nursing visit service
Number of subjects: 10749

Group type: EXPERIMENTAL
Intervention: Desire to use visiting nursing agencies' service
Number of subjects: 10749
Study: 10962675

Group type: EXPERIMENTAL
Intervention: Full strength Burow's solution (13% aluminium acetate)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 3.25% aluminium acetate solution (a quarter strength Burow's solution)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 1.3% aluminium acetate solution (1/10 strength Burow's solution)
Number of subjects: 67
Study: 8890945

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Patients with lung cancer (squamous cell carcinoma)
Number of subjects: 233
Study: 1643680

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 66
Study: 6230195

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30277807

Group type: EXPERIMENTAL
Intervention: Self-management programme (six session intervention programme including phrasing of individual action plans and group discussions)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care (received by both intervention and control groups)
Number of subjects: 118
Study: 29138916

Group type: EXPERIMENTAL
Intervention: Lateral retinaculum plasty and MPFL reconstruction
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lateral retinacular release and MPFL reconstruction
Number of subjects: 59
Study: 27298569

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine (PG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (CG)
Number of subjects: 60
Study: 25330631

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years followed by 1 year follow-up and combined with 3-year drug therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group receiving only drug therapy
Number of subjects: 120